65,437 trials
Non-alcoholic Fatty Liver Disease
Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2015-2016 Formulation of Fluzone® Quadrivalent…
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
Refractive Error
Primary: High Contrast Time-Controlled Visual Acuity (TCVA) (VA Unit) Post-Exposure to Reduced Humidity at Day 10 — 0.453; 0.341 VA unit
Bacterial Infections · Obesity
Primary: Pharmacokinetics (PK) - Clearance (Cl) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin. — 4.2; 5.7; 12.5; 10.7 L/h
Pressure Ulcers
Primary: Number of Participants With Worsening in Peri-Skin Wound.(Maceration From Baseline to 6 Weeks) — 2 participants
Choroidal Melanoma
Primary: To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal…
Peripheral Arterial Disease
Primary: Primary Safety Endpoint - Number of Participants Free From Major Adverse Events at 30 Days — 187; 69 participants
Chronic Total Occlusion of Coronary Artery · Coronary Occlusion · Coronary Artery Disease
Primary: Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF)) — 2.8 percentage of participants
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
Pancreatic Cancer
Primary: Percentage of Patients With Overall Survival at 6 Months — 26 % of participants
Depression · HIV
Primary: Antiretroviral Medication Adherence — 89.2; 87.6 observed pills taken as % of expected
Premenstrual Dysphoric Disorder
Primary: Premenstrual Tension Scale (PMTS) — 22.3; 21.4; 15.6; 16.8 units on a scale — p=0.21
Type 1 Diabetes
Primary: Time Spent <70 mg/dL - Main Phase, Night Only — 3.0; 1.1; 0.4 percentage of CGM values — p=<0.001
Primary Biliary Cirrhosis
Primary: Absolute Change From Baseline In High-density Lipoprotein (HDL) Cholesterol Concentration — -0.38 mmol/L